1310462-38-4
1310462-38-4 structure
- Name: RS-1269
- Chemical Name: RS-1269
- CAS Number: 1310462-38-4
- Molecular Formula: C35H38N4O3
- Molecular Weight: 562.714
- Create Date: 2022-07-01 12:49:38
- Modify Date: 2024-04-11 20:18:40
-
RS-1269 is a highly potent, selective CCR4 antagonist, inhibits [125I]CCL17 binding to human CCR4 with IC50 of 27.7 nM.RS-1269 also has strong affinity to displace the CCL17 binding with IC50 of 27.0 nM in CCR4-expressing CHO cells.RS-1269 displays no competitive displacement in the binding of [125I]CCL3 (MIP-1α) to CCR1 and [125I]CCL2 (MCP-1) to CCR2b.RS-1269 dose-dependently inhibited CCL17-induced migration of Th2 cells with IC50 of 5.5 nM.Orally administered RS-1269 (30 mg/kg) ameliorates ovalbumin-induced ear swelling in mice.RS-1269 also inhibited LPS-induced TNF-α production in vivo.
| Name | RS-1269 |
|---|
| Description | RS-1269 is a highly potent, selective CCR4 antagonist, inhibits [125I]CCL17 binding to human CCR4 with IC50 of 27.7 nM.RS-1269 also has strong affinity to displace the CCL17 binding with IC50 of 27.0 nM in CCR4-expressing CHO cells.RS-1269 displays no competitive displacement in the binding of [125I]CCL3 (MIP-1α) to CCR1 and [125I]CCL2 (MCP-1) to CCR2b.RS-1269 dose-dependently inhibited CCL17-induced migration of Th2 cells with IC50 of 5.5 nM.Orally administered RS-1269 (30 mg/kg) ameliorates ovalbumin-induced ear swelling in mice.RS-1269 also inhibited LPS-induced TNF-α production in vivo. |
|---|---|
| References | 1. Nakagami Y, et al. Basic Clin Pharmacol Toxicol. 2010 Oct;107(4):793-7. |
| Molecular Formula | C35H38N4O3 |
|---|---|
| Molecular Weight | 562.714 |